Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X by Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Irelan, adding:
“Pooled data on Dato-DXd in EGFR+ NSCLC from TROPION-Lung05 + 01
117 pts, median 3 prior lines, 82% prior osimertinib
– ORR: 43%
– DOR: 7 mo
– PFS: 5.8 moMucositis/stomatitis: 69%
Ocular events: 32%
ILD/pneumonitis: 4%”
Quoting Jarushka Naidoo‘s post.
“What is the role of Dato-Dxd in EGFR+ NSCLC?
– pooled analysis TropionLung01+05
– 117pts (med. 3 lines)
– ORR 43%, mPFS 5.8m, mOS 15.6m
– 60% stomatitis, g3+ 9%Reasonable option, though data not in the era of MARIPOSA+/-2″
Title: A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC
Journal: Journal of Thoracic Oncology
Authors: Myung-Ju Ahn, Aaron Lisberg, Yasushi Goto, Jacob Sands, Min Hee Hong, Luis Paz-Ares, Elvire Pons-Tostivint, Maurice Pérol, Enriqueta Felip, Shunichi Sugawara, Hidetoshi Hayashi, Byoung Chul Cho, George Blumenschein Jr., Elaine Shum, Jong-Seok Lee, Rebecca S. Heist, Robin Cornelissen, Wen-Cheng Chang, Dariusz Kowalski, Hong Zebger-Gong, Michael Chargualaf, Wen Gu, Lan Lan, Paul Howarth, Richard Joseph, Isamu Okamoto
More posts featuring Eric K. Singhi and Jarushka Naidoo on OncoDaily.